开放期刊系统

消化系统疾病药物治疗的创新疗法及实践案例

魏 箫箫, 娄 慧慧, 潘 英会

摘要

消化系统疾病严重困扰着人类的健康,尤其是随着生活节奏的加快和饮食习惯的改变,消化系统疾病的发病率逐年上升。传统疗法在缓解症状、促进康复方面发挥了重要作用,但面对复杂多变的疾病类型和个体差异,创新疗法的研究与实践显得尤为重要。本文旨在探讨消化系统疾病药物治疗的最新进展,以了解创新疗法的临床应用趋势,为消化系统疾病临床治疗提供一定的参考。

关键词

消化系统疾病;幽门螺杆菌;肿瘤;创新疗法

全文:

PDF

参考

[1]Wang Y,Du J,Zhang D,et al. Primary antibiotic resistance in Helicobacter pylori in China:a systematic review and meta-analysis[J].

J Glob Antimicrob Resist,2023,34:30-38.

[2]黄晓娟,郭小陪,延喜胜 . 分阶段服用奥美拉唑联合抗菌药物治疗 Hp 感染活动性慢性胃炎的效果观察 . 贵州医药,

2021,45(1):31-32.

[3]刘思强,马志元,石新民 . 泮托拉唑钠联合克林霉素、阿莫西林治疗 Hp 阳性十二指肠溃疡患者对其血清肽类胃肠激素

及 TGF-β1 水平的影响 . 湖南师范大学学报(医学版),2020,17(3):93-96.

[4]Van Cutsem E , di Bartolomeo M , Smyth E , et al.Trastuzumabderuxtecan in patients in the USA and Europe with

HER2-positiveadvanced gastric or gastroesophageal junction cancer with dis-ease progression on or after a trastuzumab-containing

regimen(DESTINY-Gastric02):primary and updated analyses from a single-arm,phase 2study[J].Lancet Oncol,2023,24(7):

744-756.

[5]Shen L,Bai YX,Lin XY,et al.First-line(1L)nivolumab(NIVO)pluschemotherapy(chemo)vs chemoin patients(pts)with

advanced ga-stric cancer,gastroesophageal junction cancer,and esophagealadenocarcinoma(GC/GEIC/EAC):checkmate 649 Chinese

subgro-up analysis 4-year(yr)follow-up[J].JClin Oncol,2024,42(3_suppl):318.

[6]YIN J,YUAN J,LI Y,et al. Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma:a phase

1b trial[J]. Nat Med,2023,29(8):2068-2078.

[7]LI Y,JI Y,SHEN L,et al. Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum

versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first¬line treatment of patients with locally advanced,

metastatic,or recurrent esophageal squamous cell carcinoma[J]. Front Oncol,2022,12:1015302.

[8]钟 轩,王红钰,高建超,等.木犀草素通过 CTGF/EGFR 通路对人结肠癌细胞 LoVo 增殖和凋亡的影响[J].中南医学科学杂

志,2022,50(4):486-490.

[9]刘卓.贝伐珠单抗联合 FOLFOX4 方案治疗晚期转移性结肠癌患者的临床疗效及安全性[J].临床合理用药杂志,2022,15(12):

96-98.

[10]董晓,陈胜良.多巴胺 D2 受体拮抗剂消化专科合理应用中国专家意见[J].胃肠病学,2020,25(11):673-677.

[11]Weinbe r g,D. S.,Smalley,etal.American Gastroenterological Association Institute guideline o n the pharmacological management

of irritable bowel syndrome[J]. Gastroenterology,2015,148(2).

[12]Yong Wen,Jun Li,Qing Long,etal. The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel

syndrome:A systematic review and meta-analysis based on seventeen randomized controlled trials[J]. International Journal of Surgery,

2020,79(prepublish).

作者简介:

第一作者:魏箫箫(1988.05.21),女,汉族,山东省济南市,硕士,主管药师,研究方向:药剂;

第二作者:娄慧慧(1989.11.16),女,汉族,山东省济南市槐荫区南辛北街,研究生,中药师,研究方向:中药理论的临床

应用;中药药理毒理学研究;

第三作者:潘英会(1988.11.12),女,汉族,山东省济南市,本科,检验师,研究方向:医学检验。


(0 摘要 Views, 0 PDF Downloads)

Refbacks

  • 当前没有refback。